Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Juni 2019 08:00 ET | Quelle: Oncternal Therapeutics

Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers...
03. Juni 2019 16:00 ET | Quelle: Oncternal Therapeutics

Oncternal Therapeutics Announces Updated Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib

SAN DIEGO, June 03, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potential first-in-class product candidates for cancers with...
15. Mai 2019 17:01 ET | Quelle: Oncternal Therapeutics

Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual Meeting

SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potential first-in-class therapeutic candidates for cancers...